Plans with lower deductibles and co-payments are creating lower aggregate cost.


Plans with lower deductibles and co-payments are creating lower aggregate cost, as evidenced by a nationwide move to medical homes and employer-sponsored on-site health clinics with lower deductibles and co-payments. Ross, who has 20 years experience in worker benefits, conducted an evaluation of 200,000 program people covered under multiple employer self-funded health programs. The two-year analysis viewed promises totaling $800 million. Among the results: 85 percent of the group accounted for $155 million or 19 percent of annual claims. This larger %age averaged $456 per member. 15 percent of the group accounted for the remaining $645 million or 81 percent of annual promises.ARUP Laboratories was among three independent labs that participated in the PRESEPT research, a nearly 8,000 subject prospective study of the screening people which validated Septin 9 as a delicate blood-centered biomarker of colorectal tumor. PRESEPT was sponsored by Epigenomics AG, and executed beneath the direction of an independent clinical study steering committee. Preliminary outcomes of the analysis were lately presented at the 2010 Digestive Disease Week this spring, with publications anticipated in the near term. ARUP Laboratories licensed the Septin 9 biomarker from Epigenomics AG in August 2009 to be able to develop and commercialize a blood-based colorectal screening test.